Cinctive Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Cinctive Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,766	Closed	-$599K	–	479
2025 Q2	$599K	Buy	+4,766	New	+$547K	0.03%	304
2025 Q1	–	Sell	-16,366	Closed	-$2.23M	–	415
2024 Q4	$2.23M	Buy	+16,366	New	+$2.02M	0.11%	209
2024 Q2	–	Sell	-9,983	Closed	-$1.38M	–	487
2024 Q1	$1.38M	Buy	+9,983	New	+$1.36M	0.06%	253
2022 Q1	–	Sell	-67,825	Closed	-$5.78M	–	609
2021 Q4	$5.78M	Sell	67,825 -35,948	-35%	-$3.31M	0.25%	126
2021 Q3	$9.95M	Buy	103,773 +26,734	+35%	+$2.53M	0.49%	44
2021 Q2	$7.5M	Buy	77,039 +28,248	+58%	+$2.71M	0.35%	76
2021 Q1	$4.75M	Buy	+48,791	New	+$5.12M	0.29%	138
2020 Q3	–	Sell	-33,393	Closed	-$4.07M	–	340
2020 Q2	$4.07M	Sell	33,393 -1,289	-4%	-$142K	0.47%	75
2020 Q1	$3M	Buy	+34,682	New	+$3.39M	0.67%	48

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cinctive Capital Management's NBIX Position: Q3 2025 in Review

Cinctive Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 4,766 shares — an estimated $599K sold.

Cinctive Capital Management first reported a position in NBIX in Q1 2020 and held it in 9 quarters. The position peaked at $9.95M in Q3 2021. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Cinctive Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Cinctive Capital Management sold 4,766 Neurocrine Biosciences shares in Q3 2025, an estimated $599K.
Cinctive Capital Management first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 9 quarters.
Cinctive Capital Management's Neurocrine Biosciences position peaked at $9.95M in Q3 2021.
649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.